{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:50:09Z","timestamp":1768992609421,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Novel therapies are necessary to improve outcomes for patients with squamous cell carcinomas (SCC) of the head and neck. Historically, vaccinia virus was administered widely to humans as a vaccine and led to the eradication of smallpox. We examined the therapeutic effects of an attenuated, replication-competent vaccinia virus (GLV-1h68) as an oncolytic agent against a panel of six human head and neck SCC cell lines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>All six cell lines supported viral transgene expression (\u03b2-galactosidase, green fluorescent protein, and luciferase) as early as 6 hours after viral exposure. Efficient transgene expression and viral replication (&gt;150-fold titer increase over 72 hrs) were observed in four of the cell lines. At a multiplicity of infection (MOI) of 1, GLV-1h68 was highly cytotoxic to the four cell lines, resulting in \u2265 90% cytotoxicity over 6 days, and the remaining two cell lines exhibited &gt;45% cytotoxicity. Even at a very low MOI of 0.01, three cell lines still demonstrated &gt;60% cell death over 6 days. A single injection of GLV-1h68 (5 \u00d7 10<jats:sup>6<\/jats:sup> pfu) intratumorally into MSKQLL2 xenografts in mice exhibited localized intratumoral luciferase activity peaking at days 2\u20134, with gradual resolution over 10 days and no evidence of spread to normal organs. Treated animals exhibited near-complete tumor regression over a 24-day period without any observed toxicity, while control animals demonstrated rapid tumor progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>These results demonstrate significant oncolytic efficacy by an attenuated vaccinia virus for infecting and lysing head and neck SCC both <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>, and support its continued investigation in future clinical trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1476-4598-8-45","type":"journal-article","created":{"date-parts":[[2009,7,7]],"date-time":"2009-07-07T06:14:19Z","timestamp":1246947259000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Oncolytic vaccinia therapy of squamous cell carcinoma"],"prefix":"10.1186","volume":"8","author":[{"given":"Zhenkun","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Brader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanhai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong A","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aladar A","family":"Szalay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuman","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,7,6]]},"reference":[{"key":"430_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322\/CA.2007.0010.","journal-title":"CA Cancer J Clin"},{"key":"430_CR2","doi-asserted-by":"crossref","unstructured":"Vokes EE, Weichselbaum RR, Lippman SM, Hong WK: Head and neck cancer, 1993. N Engl J Med. 328: 184-191. 10.1056\/NEJM199301213280306.","DOI":"10.1056\/NEJM199301213280306"},{"key":"430_CR3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/gt.2008.72","volume":"15","author":"TC Liu","year":"2008","unstructured":"Liu TC, Kirn D: Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther. 2008, 15: 877-884. 10.1038\/gt.2008.72.","journal-title":"Gene Ther"},{"key":"430_CR4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ymthe.2004.10.015","volume":"11","author":"Y Shen","year":"2005","unstructured":"Shen Y, Neumunaitis J: Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol Ther. 2005, 11: 180-195. 10.1016\/j.ymthe.2004.10.015.","journal-title":"Mol Ther"},{"key":"430_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nbt937","volume":"22","author":"YA Yu","year":"2004","unstructured":"Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I, Goebel W, Szalay AA: Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol. 2004, 22: 313-320. 10.1038\/nbt937.","journal-title":"Nat Biotechnol"},{"key":"430_CR6","doi-asserted-by":"publisher","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-07-0146","volume":"67","author":"Q Zhang","year":"2007","unstructured":"Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, Marincola FM, Szalay AA: Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 2007, 67: 10038-10046. 10.1158\/0008-5472.CAN-07-0146.","journal-title":"Cancer Res"},{"key":"430_CR7","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.surg.2007.09.017","volume":"142","author":"SF Lin","year":"2007","unstructured":"Lin SF, Yu Z, Riedl C, Woo Y, Zhang Q, Yu YA, Timiryasova T, Chen N, Shah JP, Szalay AA, Fong Y, Wong RJ: Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery. 2007, 142: 976-983. 10.1016\/j.surg.2007.09.017.","journal-title":"Surgery"},{"key":"430_CR8","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1210\/jc.2008-0316","volume":"93","author":"SF Lin","year":"2008","unstructured":"Lin SF, Price DL, Chen CH, Brader P, Li S, Gonzalez L, Zhang Q, Yu YA, Chen N, Szalay AA, Fong Y, Wong RJ: Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab. 2008, 93: 4403-4407. 10.1210\/jc.2008-0316.","journal-title":"J Clin Endocrinol Metab"},{"key":"430_CR9","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1089\/hum.2008.036","volume":"19","author":"KJ Kelly","year":"2008","unstructured":"Kelly KJ, Woo Y, Brader P, Yu Z, Riedl C, Lin SF, Chen N, Yu YA, Rusch VW, Szalay AA, Fong Y: Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma. Hum Gene Ther. 2008, 19: 774-82. 10.1089\/hum.2008.036.","journal-title":"Hum Gene Ther"},{"key":"430_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/1535-7163.MCT-08-0533","volume":"8","author":"YA Yu","year":"2009","unstructured":"Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, Fong Y, Szalay AA: Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther. 2009, 8: 141-151. 10.1158\/1535-7163.MCT-08-0533.","journal-title":"Mol Cancer Ther"},{"key":"430_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2119\/molmed.2009.00014","volume":"15","author":"N Chen","year":"2009","unstructured":"Chen N, Zhang Q, Yu YA, Stritzker J, Brader P, Schirbel A, Samnick S, Serganova I, Blasberg R, Fong Y, Szalay AA: A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep tissue imaging. Mol Med. 2009, 15: 144-151.","journal-title":"Mol Med"},{"key":"430_CR12","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-08-3236","volume":"15","author":"P Brader","year":"2009","unstructured":"Brader P, Kelly K, Chen N, Yu YA, Zhang Q, Zanzonico P, Burnazi EM, Ghani ER, Serganova I, Hricak H, Szalay AA, Fong Y, Blasberg R: Imaging a genetically engineered oncolytic vaccinia virus (GLV-1h99) using a human norepinephrine transporter (hNET) reporter gene. Clin Cancer Res. 2009, 15: 3791-801. 10.1158\/1078-0432.CCR-08-3236.","journal-title":"Clin Cancer Res"},{"key":"430_CR13","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S0140-6736(73)92215-0","volume":"1","author":"JC Sharp","year":"1973","unstructured":"Sharp JC, Fletcher W: Experience of anti-vaccina immunoglobulin in the United Kingdom. Lancet. 1973, 1: 656-659. 10.1016\/S0140-6736(73)92215-0.","journal-title":"Lancet"},{"key":"430_CR14","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1128\/AAC.48.6.2267-2273.2004","volume":"48","author":"J Neyts","year":"2004","unstructured":"Neyts J, Leyssen P, Verbeken E, De Clercq E: Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob Agents Chemother. 2004, 48: 2267-73. 10.1128\/AAC.48.6.2267-2273.2004.","journal-title":"Antimicrob Agents Chemother"},{"key":"430_CR15","doi-asserted-by":"publisher","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","volume":"79","author":"G Yang","year":"2005","unstructured":"Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RL, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D, Jordan R: An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol. 2005, 79: 13139-49. 10.1128\/JVI.79.20.13139-13149.2005.","journal-title":"J Virol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-8-45.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T23:34:46Z","timestamp":1630452886000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-8-45"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,6]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["430"],"URL":"https:\/\/doi.org\/10.1186\/1476-4598-8-45","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,6]]},"assertion":[{"value":"26 March 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"45"}}